Glenmark Pharma gets UK MHRA approval for Maloff Protect to treat malaria

glenmarkincGlenmark Pharmaceuticals Europe (Glenmark) has received final approval by the MHRA (Medicines and Healthcare products Regulatory Agency) for Maloff Protect (250mg/100mg atovaquone/proguanil film-coated tablets), anti-malarial medication, as a pharmacy license in the United Kingdom.

Maloff Protect will be used in the prevention of malaria in adults travelling to areas where malaria is prevalent. Maloff Protect contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK. Under this approval, patients will be able to purchase Maloff Protect without a prescription.

Achin Gupta, executive vice president & business head Europe, Glenmark Pharma said, “The launch of Maloff Protect as an OTC product is a significant development for the UK and our entire European business. This is our first major OTC launch in the UK. We are glad that the MHRA, UK has granted us the pharmacy license and thus making the product accessible to millions of citizens who visit countries where Malaria is prevalent. The launch also marks our entry into the OTC segment primarily through the pharmacy chains. We will continue exploring this route to grow the business.”

Glenmark’s current portfolio consists of +100 SKUs authorized for distribution in the UK, both in-licensed as well as Glenmark’s own products. In addition to this approval Glenmark UK continues to identify and explore both internal as well as external development partnerships to supplement and accelerate the growth of its existing opportunities and future portfolio.


Rate this item
(0 votes)
Login to post comments
Go to top